0	pancreatic cancer	NA	NA	ABSTRACT	In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined.
0	pancreatic cancer	NA	NA	ABSTRACT	To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4).
0	NA	NA	rs78417682	ABSTRACT	Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 x 10-8).
1	PANcreatic Disease	NOC2L	rs13303010	ABSTRACT	Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 x 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 x 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 x 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 x 10-8).
0	pancreatic cancer	NA	rs78417682	ABSTRACT	rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA.
1	pancreatic cancer	NOC2L	NA	ABSTRACT	Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene
0	pancreatic cancer	NA	NA	ABSTRACT	Genetic variants associated with susceptibility to pancreatic cancer have been identified using genome wide association studies (GWAS).
0	pancreatic cancer	NA	NA	ABSTRACT	Here, the authors combine data from over 9000 patients and perform a meta-analysis to identify five novel loci linked to pancreatic cancer
0	pancreatic cancer	NA	NA	INTRO	Pancreatic cancer is currently the third leading cause of cancer-related deaths in the United States and the fifth leading cause in Europe, and is predicted to become the second leading cause of cancer-related deaths in the United States by 2030.
0	pancreatic cancer	NA	NA	INTRO	Incidence rates of pancreatic cancer have also gradually increased.
0	pancreatic cancer	NA	NA	INTRO	Genetic susceptibility plays an important role in pancreatic cancer risk through mutations in known genes for hereditary cancer or hereditary pancreatitis, and common genetic variants identified through genome-wide association studies (GWAS)
0	pancreatic cancer	NA	NA	INTRO	With the aim of identifying additional common pancreatic cancer risk loci, the Pancreatic Cancer Cohort Consortium (PanScan: https://epi.grants.cancer.gov/PanScan/) and the Pancreatic Cancer Case-Control Consortium (PanC4: http://www.panc4.org/) have performed GWAS of pancreatic ductal adenocarcinoma (PDAC) in populations of European ancestry.
0	pancreatic cancer	NR5A2	NA	INTRO	These studies, namely PanScan I, PanScan II, PanScan III, and PanC4, have led to the identification of 13 genomic loci carrying 17 independent pancreatic cancer risk signals on chromosomes 1q32.1 (two independent signals in NR5A2), 2p14 (ETAA1), 3q28 (TP63), 5p15.33 (three independent risk loci in the CLPTM1L-TERT gene region), 7p14.1 (SUGCT), 7q23.2 (LINC-PINT), 8q24.1 (two independent risk loci in the MYC-PVT1 gene region), 9q34.2 (ABO), 13q12.2 (PDX1), 13q22.1 (non-genic), 16q23.1 (BCAR1), 17q24.3 (LINC00673), and 22q12.1 (ZNRF3).
0	PANcreatic Disease	TERT	NA	INTRO	A fourth independent risk locus at 5p15.33 (TERT) was identified through a candidate gene analysis by the PANcreatic Disease ReseArch (PANDoRA) case-control consortium.
0	pancreatic cancer	DAB2	NA	INTRO	GWAS in populations from China and Japan have identified eight additional GWAS significant pancreatic cancer risk loci on chromosomes 5p13.1 (DAB2), 6p25.3 (FOXQ1), 7q36.2 (DPP6), 12p11.21 (BICD1), 10q26.11 (PRLHR), 21q21.3 (BACH1), 21q22.3 (TFF1), and 22q13.32 (FAM19A5).
0	NA	NA	NA	INTRO	The overlap among loci identified in the European and Asian ancestry scans with current sample sizes is limited
0	pancreatic cancer	NA	NA	INTRO	Here we report the findings of the largest Pancreatic Cancer GWAS study to date.
0	NA	NA	NA	INTRO	Five novel regions of association were identified.
0	NA	NA	rs78417682	INTRO	A locus at rs78417682 (7p12/TNS3, P = 4.35 x 10-8) was identified in meta-analysis of the PanScanI/II, PanScanIII, and PanC4 data.
1	NA	NOC2L	rs13303010	INTRO	Four additional loci, rs13303010 at 1p36.33 (NOC2L, P = 8.36 x 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 x 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 x 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 x 10-8) were identified after replication in additional cases and controls from the PANDoRA consortium
0	pancreatic cancer	NA	NA	RESULTS	In the current study, we performed the largest association analysis of pancreatic cancer risk to date, including 9040 individuals diagnosed with pancreatic cancer and 12,496 control individuals of European ancestry (Supplementary Table 1) from four GWAS studies (PanScan I, PanScan II, PanScan III, and PanC4).
0	NA	NA	NA	RESULTS	These individuals were previously genotyped on the Illumina HumanHap550, 610-Quad, OmniExpress, and OmiExpressExome arrays, respectively.
0	NA	NA	NA	RESULTS	Because of the extensive overlap of variants on the arrays, data from PanScan I and PanScan II were analyzed jointly, while PanScan III and PanC4 were each analyzed separately.
0	NA	NA	NA	RESULTS	Imputation was performed using the 1000 G (Phase 3, v1) reference data set.
0	NA	NA	NA	RESULTS	After quality control 11,381,182 variants were analyzed for 21,536 individuals (7167 in PanScan I+II, 6785 in PanScan III, and 7584 in PanC4).
0	NA	NA	NA	RESULTS	A quantile-quantile plot (Supplementary Figure 1) showed little evidence of systematic inflation (lambda = 1.002 for PanScan I+II, lambda = 1.051 for PanScan III, lambda = 1.025 for PanC4, and lambda = 1.05 for the meta-analysis)
0	pancreatic cancer	NA	NA	FIG	Association results, recombination hotspots, and LD plots for new pancreatic cancer susceptibility regions.
0	NA	NA	NA	FIG	The top half of each panel shows the association results for the meta-analysis of PanScan I+II, PanScan III, and PanC4 (gray diamonds).
0	NA	NA	NA	FIG	The results for the replication of the marker SNP at each locus are shown for PANDoRA (light blue diamonds) and the combined meta-analysis results (red diamonds).
0	NA	NA	NA	FIG	Overlaid are likelihood ratio statistics estimating putative recombination hotspots across the region based on the inference using the CEU 1000 G Phase 3 data.
0	NA	NA	NA	FIG	Genomic coordinates are plotted on the x axis (Genome build hg19), P values for the association analysis are shown on the left y axis, and recombination hotspot likelihood ratio on the right y axis.
0	NA	NA	NA	FIG	The bottom half of each panel shows LD heat maps based on r2 values from the 1000 G Phase 3 CEU population for all variants included in the analysis.
0	NA	NA	NA	FIG	Shown are results for chromosomes 1p36.33 (a), 8q21.11 (b), 17q12 (c), 18q21.32 (d), and 7p12 (e
0	NA	NA	NA	RESULTS	In a fixed-effect meta-analysis of PanScan I+II, PanScan III, and PanC4, we observed robust associations at our previously identified susceptibility loci in individuals of European ancestry (Supplementary Table 2).
0	NA	TNS3	NA	RESULTS	We also noted one novel locus that met the genome-wide significance threshold (P < 5 x 10-8: Wald test) at chromosome 7p12 in the TNS3 gene, and nine additional promising loci (P < 1 x 10-6: Wald test).
0	pancreatic cancer	NA	NA	RESULTS	These 10 loci were carried forward to an independent replication in up to 2737 pancreatic cancer cases and 4752 control individuals from the PANcreatic Disease ReseArch (PANDoRA) consortium.
1	pancreatic cancer	NOC2L	rs13303010	RESULTS	In a combined meta-analysis of up to 11,537 pancreatic cancer cases and 17,107 control individuals from PanScan I+II, PanScan III, PanC4, and PANDoRA, we identified three additional loci of genome-wide significance: rs13303010 at 1p36.33 (NOC2L, odds ratio (OR) = 1.26; 95% confidence interval (CI) 1.19-1.35, P = 8.36 x 10-14: Wald test), rs2941471 at 8q21.11 (HNF4G, OR = 0.89, 95% CI 0.85-0.93, P = 6.60 x 10-10: Wald test), and rs4795218 at 17q12 (HNF1B, OR = 0.88, 95% CI 0.84-0.92, P = 1.32 x 10-8: Wald test).
0	NA	GRP	rs1517037	RESULTS	A locus that was previously reported to be suggestive in the PanC4 study at 18q21.32 in the GRP gene also surpassed the significance threshold (rs1517037, OR = 0.86, 95% CI 0.80-0.91, P = 3.28 x 10-8: Wald test) in our meta-analysis.
0	NA	NA	NA	RESULTS	(Table 1 and Fig.
0	NA	NA	NA	RESULTS	1).
1	pancreatic cancer	TNS3	rs73328514	RESULTS	The single-nucleotide polymorphism (SNP) at 7p12 in TNS3 (rs73328514) was not significantly associated with pancreatic cancer in PANDoRA (OR = 0.94, PPANDoRA = 0.31; OR = 0.85, PCombined = 1.35 x 10-7: Wald test)
1	NA	NOC2L	rs13303010	RESULTS	The marker SNP at 1p36.33 (rs13303010) maps to the first intron of the NOC2L gene, which encodes the nucleolar complex protein 2 homolog (NOC2-like protein, also known as novel INHAT repressor), an inhibitor of histone acetyltransferase (HAT) activity and transcriptional repressor.
0	NA	p53	NA	RESULTS	This protein also directly binds to p53, stabilizing an interaction between the mitotic kinase Aurora B and p53, resulting in inhibition of p53-mediated transcriptional activation.
1	cancers	NOC2L	NA	RESULTS	Likewise, NOC2-like protein binds and inhibits transcriptional activity of the closely related tumor suppressor protein, p63 (TAp63).
0	pancreatic cancer	TP63	NA	RESULTS	Notably, we have previously identified a pancreatic cancer risk locus intronic to the TP63 gene
1	NA	HNF4G	rs2941471	RESULTS	At chromosome 8q21.11, the newly associated SNP (rs2941471) is intronic to HNF4G, which encodes hepatocyte nuclear factor 4 gamma, a transcription factor (TF) of the nuclear receptor superfamily.
0	insulin deficiency	Hnf4g	NA	RESULTS	Mice lacking Hnf4g have higher numbers of pancreatic beta-cells, increased glucose-induced insulin secretion, and improved glucose tolerance.
1	NA	NA	rs2941471	RESULTS	Of the multiple GWAS that have reported association signals at this locus for other conditions, the variant with the highest linkage disequilibrium (LD) with our pancreatic cancer-associated variant, rs2941471, has been significantly associated with variations in serum urate concentrations (rs2941484, r2 = 0.56, in 1000 G EUR).
0	pancreatic cancer	NA	NA	RESULTS	Interestingly, we have previously shown that urate levels are associated with pancreatic cancer risk.
1	obese	HNF4G	rs2941471	RESULTS	Additional variants in the HNF4G gene region, including those significantly associated with body mass index (BMI), obesity, and breast cancer are less correlated with rs2941471 (r2 = 0.02-0.12)
1	NA	HNF1B	rs4795218	RESULTS	The signal at 17q12 (rs4795218) maps to the fourth intron of HNF1B, encoding another member of the hepatocyte nuclear factor family.
1	NA	HNF1B	NA	RESULTS	HNF1B plays an important role in pancreatic development, acting in a transcriptional network that controls the differentiation of multipotent progenitor cells to acinar, ductal, and endocrine cells.
1	diabetes	HNF1B	NA	RESULTS	Mutations in HNF1B account for a small percentage (1-2%) of maturity onset diabetes of the young (MODY).
1	Breast and prostate cancer	HNF1B	rs4795218	RESULTS	In addition, variants in the HNF1B gene region that are modestly linked with rs4795218 have previously been associated with the development of prostate cancer (rs4794758, r2 = 0.59 in 1000 G EUR).
1	cancers	NA	rs4430796	RESULTS	Although additional variants in this region have been associated with other cancers including prostate, endometrial, and testicular cancers, they do not appear to mark the same signal (rs4430796, rs11263763, rs7501939, respectively, r2 with rs4795218 <= 0.005 in 1000 G EUR)
0	NA	HNF1A	rs1182933	RESULTS	The two novel risk loci in genes of the hepatocyte nuclear factor family are intriguing in light of our previously published suggestive evidence of association with other members of this family, including a locus at 12q24.31 in the HNF1A gene (rs1182933, OR = 1.11, P = 3.49 x 10-7: Wald test) and a locus on 20q13.11 ~20 kb downstream of the HNF4A gene (rs6073450, OR = 1.09, P = 4.55 x 10-6: Wald test; Supplementary Table 3).
0	NA	NA	NA	RESULTS	Members of this family of TFs play important roles in pancreatic development and regulate specific gene expression programs in pancreatic acini, pancreatic islets, and hepatocytes in adults.
0	NA	HNF1A	NA	RESULTS	Importantly, HNF1A appears to be a critical member of a signaling network that maintains homeostasis in the adult pancreas.
0	cancers	HNF1A	NA	RESULTS	We have also previously shown that HNF1A may be a tumor suppressor gene in the pancreas.
1	pancreatic	HNF4A	NA	RESULTS	Inherited mutations in several genes of this family cause pancreatic beta cell dysfunction resulting in MODY: HNF4A (MODY 1), HNF1A (MODY 3), and HNF1B (MODY 5).
0	Type 2 diabetes	NA	NA	RESULTS	Common variants in or close to some of these genes have also been significantly associated with type 2 diabetes (T2D) and body mass index (BMI)/obesity, both known epidemiologic risk factors for pancreatic cancer.
1	pancreatic cancer	NA	NA	RESULTS	However, the low LD between those signals on 8q21.11/HNF4G (PDAC-rs2941471 and BMI-rs17405819, r2 = 0.05), 17q12/HNF1B (PDAC-rs4795218 and T2D-rs4430796, r2 = 0.0007), and 12q24.31/HNF1A (PDAC-rs7310409 and T2D-rs12427353, r2 = 0.18) indicates that the underlying functional mechanism for the pancreatic cancer GWAS signals may differ from those for adult-onset T2D and BMI
0	pancreatic	GRP	rs1517037	RESULTS	At 18q21.32, the signal marked by rs1517037 is ~10 kb upstream of the GRP gene, which encodes a member of the bombesin-like family of gastrin-releasing peptides that stimulates the release of gastrointestinal hormones, including amylase, a marker of acute pancreatitis.
0	inflammatory bowel disease	NA	NA	RESULTS	Correlated variants at this locus (r2 = 0.82-1.00) are associated with inflammatory bowel disease (IBD) and BMI
1	NA	TNS3	rs73328514	RESULTS	The locus at 7p12 is marked by an intronic SNP (rs73328514) in TNS3.
0	NA	TNS3	NA	RESULTS	This gene encodes Tensin-3, a member of a family of focal adhesion-associated proteins (Tensin-1 through Tensin-4) that regulate cell adhesion and migration and may play a role in metastasis
1	NA	SMC2	rs2417487	RESULTS	We identified suggestive evidence for additional risk loci in the meta-analysis of PanScan and PanC4 data; at 9q31.1 in the SMC2 gene (rs2417487, P = 1.49 x 10-7: Wald test), at 4q31.22 near EDNRA (rs6537481, P = 1.15 x 10-7: Wald test), and at 16q24.1 near LINC01081/LINC00917 (rs7200646, P = 1.39 x 10-7: Wald test) but these were not significantly associated in PANDoRA (P = 0.38, 0.91 and 0.93, respectively: Wald tests; Supplementary Table 4).
1	NA	SMC2	NA	RESULTS	SMC2 encodes a subunit of condensin and is necessary for chromosome organization, cell division, and DNA repair.
0	pancreatic cancer	EDNRA	NA	RESULTS	EDNRA encodes the endothelin-1 receptor and has been associated with pancreatic cancer prognosis.
0	cancers	FOXF1	NA	RESULTS	The locus on 16q24.1 lies ~200-300 kb upstream of a cluster of genes of the forkhead family of TFs (FOXF1, FOXC2, and FOXL1), known for their roles in development, cell proliferation, and several diseases, including cancer
0	pancreatic cancer	NA	NA	RESULTS	We further estimated a polygenetic risk score (PRS) for pancreatic cancer using the 22 independent genome-wide significant risk SNPs in the Caucasian population.
0	pancreatic cancer	NA	NA	RESULTS	The OR for pancreatic cancer among individuals above the 90th percentile the risk distribution was 2.20 (95% CI 1.83-2.65) compared with those with a PRS in the 40-60th percentile (Supplementary Table 5).
0	pancreatic cancer	NA	rs9502893	RESULTS	We also assessed eight pancreatic cancer risk loci identified in Chinese and Japanese individuals in our data and noted one nominally significant locus in the combined PanScan and PanC4 results (6p25.3, rs9502893, OR = 0.94, 95% CI 0.92-0.97, P = 0.009: Wald test; Supplementary Table 6)
0	pancreatic cancer	NA	NA	RESULTS	Pathway enrichment analysis for genes in currently known pancreatic cancer risk loci was performed using gene set enrichment analysis (GeneCodis; http://genecodis.cnb.csic.es/analysis) and Data-Driven Expression Prioritized Integration for Complex Traits (DEPICT; https://data.broadinstitute.org/mpg/depict/).
0	diabetes	NA	NA	RESULTS	"The most significant enrichment was seen for the terms ""Maturity onset diabetes of the young"" (Kyoto Encyclopedia of Genes and Genomes (KEGG), P = 5.5 x 10-9, Hypergeometric distribution test), ""Sequence-specific DNA-binding transcription factor activity"" (GO Molecular Function, P = 3.1 x 10-4), ""Cellular response to UV"" (GO Biological Process, P = 4.2 x 10-4, Hypergeometric distribution test) as well as multiple gastrointestinal tissues (DEPICT, P = 5.1 x 10-5-0.004, Welch's t-test; Supplementary Tables 7 and 8)"
0	pancreatic cancer	NA	NA	TABLE	Expression quantitative trait loci (eQTLs) for marker SNPs on chromosomes 1p36.33 and 8q21.11 in histologically normal pancreatic tissue samples from GTeX (n = 149) and LTG (n = 95) as well as pancreatic tumor samples from TCGA (PDAC, n = 115
0	NA	NA	NA	FIG	Functional analysis of the 1p36.33 risk locus.
0	NA	NA	NA	FIG	a The set of most likely functional variants at 1p36.33 and their P value rank (1-10, in red) is shown as well as overlapping RefSeq genes on chr1: 885,555-904,522 (NCBI GRCh37/Hg19).
0	NA	NA	NA	FIG	ENCODE data for histone modification marks (H3K4me1, H3K4me3, H3K27Ac) are indicated by colored density plots.
0	allergy	NA	NA	FIG	Open chromatin (DNase hypersensitivity regions, DNase clusters) and binding of transcription factors (TF ChIP) are indicated by horizontal bars.
0	NA	NA	NA	FIG	The numbers next to each bar indicate the number of cell lines with DNase clusters, or the number of different transcription factors bound across all tested cell lines.
0	NA	NA	NA	FIG	The panel is adapted from the UCSC Genome Browser.
0	pancreatic cancer	NA	NA	FIG	b Expression QTLs in histologically normal autopsy-derived pancreatic tissues (n = 149) from the GTEx consortium (GTEx), the Laboratory of Translational Genomics histologically normal adjacent-to-tumor pancreatic tissue set (LTG, n = 95), and the TCGA pancreatic cancer tissue set (TCGA/PAAD, n = 115).
1	NA	NOC2L	NA	FIG	Normalized NOC2L expression is shown on the y axis and genotypes at the marker SNP at 1p36.33 on the x axis.
0	NA	NA	NA	FIG	Risk-increasing alleles are marked in red.
0	NA	NA	NA	FIG	Note that no samples in the LTG and TCGA/PAAD sets were of the minor homozygous risk genotype (GG).
0	NA	NA	NA	FIG	The box-and-whisker plots show the median (horizontal middle line within each box), interquartile range (top and bottom horizontal lines of each box), and 1.5 times the IQR (whiskers).
1	NA	NA	rs13303160	FIG	c Analysis of the effects of 1p36.33 variants on transcription factor motifs for rs13303160 (r2 = 0.93 with rs13303010 in 1000 G EUR).
0	NA	SMARCC1	NA	FIG	The risk allele (C) at this marker alters predicted DNA-binding motifs for SMARCC1 and AP-1 protein
0	NA	NA	NA	RESULTS	To begin unraveling the functional consequences of the newly discovered risk alleles, we performed expression quantitative trait locus (eQTL) analyses in three independent pancreatic tissue sample sets.
0	NA	NA	NA	RESULTS	We first assessed eQTLs in the publicly available Genotype-Tissue Expression (GTEx) project data for 149 histologically normal pancreatic tissue samples (including genes in a 1MB window centered on the marker SNP at each locus).
0	pancreatic cancer	NA	NA	RESULTS	Nominally significant eQTLs (P < 0.05) from this analysis (Supplementary Table 9, Supplementary Figure 2) were then carried forward to replication in two additional sample sets: (1) 95 histologically normal pancreatic samples (Laboratory of Translational Genomics, Laboratory of Translational Genomics (LTG) set) and (2) 115 pancreatic tumors (The Cancer Genome Atlas, TCGA, Pancreatic Adenocarcinoma, PAAD, samples; Table 2).
1	NA	NOC2L	rs13303010	RESULTS	The most notable eQTL in this analysis was seen for 1p36.33, where the risk-increasing allele at rs13303010 was associated with higher NOC2L expression in all three data sets (GTEx: P = 0.01, beta = 0.39; LTG: P = 0.019, beta = 0.41; TCGA: P = 0.043, beta=0.49: T-statistic; Fig.
0	NA	NA	NA	RESULTS	2b).
0	NA	KLHL17	NA	RESULTS	An additional eQTL for a nearby gene, KLHL17, was significant in GTEx (P = 2.1 x 10-5, beta = -0.42: T-statistic) but not in LTG (P = 0.131, beta = -0.32: T-statistic) or TCGA (P = 0.654, beta = -0.11: T-statistic).
1	NA	HNF4G	NA	RESULTS	At 8q21.11, the risk allele (rs2941471-A) was associated with higher expression of HNF4G in GTEx (P = 0.038, beta = 0.15: T-statistic) and LTG (P = 0.024, beta = 0.28: T-statistic) samples, but not in TCGA (P = 0.80, beta = -0.029: T-statistic)
1	NA	NA	NA	RESULTS	At 1p36.33/NOC2L, we analyzed the set of variants most likely to be functional (LR > 1:100, n = 10) for overlap with transcriptionally active chromatin and effects on predicted TF-binding sites.
1	NA	NA	rs13303160	RESULTS	The most notable variant in this analysis was rs13303160 (r2 = 0.93 with rs13303010) that overlaps open chromatin and prominent histone modification marks in ENCODE data (Fig.
0	NA	SMARCC1	NA	RESULTS	2a, Supplementary Table 10) and where the risk allele is predicted to strongly disrupt TF-binding motifs for SMARCC1 (also known as BAF155) and several AP-1 proteins (Fig.
0	NA	NA	NA	RESULTS	2c, Supplementary Table 11).
1	NA	SMARCC1	rs13303160	RESULTS	These analyses suggest that altered SMARCC1 or AP-1 binding at rs13303160 may lead to higher levels of NOC2L mRNA.
1	NA	NOC2L	NA	RESULTS	An increase in NOC2L protein would be expected to result in lower levels of histone acetylation and repression of p53 and p63 transcriptional activity.
1	pancreatic cancer	NOC2L	NA	RESULTS	We also assessed differential expression of NOC2L (and additional genes at the five novel loci) in pancreatic tumors and noted a 3.98-fold (P = 9.69 x 10-10: EdgeR, Exact test) increased expression in pancreatic cancer cell lines (n = 9) as compared with histologically normal pancreatic tissue samples (n = 10; Supplementary Table 12)
0	pancreatic cancer	NA	NA	DISCUSS	This study demonstrates the power of large-scale collaborations in identifying new risk loci for pancreatic cancer, a deadly disease that presents challenges in accruing large sample sets for genetic studies.
0	pancreatic cancer	NA	NA	DISCUSS	We herein add to the number of pancreatic cancer risk loci in or close to genes involved in MODY.
0	NA	NA	NA	DISCUSS	As these genes also play roles in pancreatic development and acinar homeostasis, they may help explain underlying mechanisms at these loci.
0	NA	NA	NA	DISCUSS	However, due to the low LD with BMI and T2D GWAS variants, the underlying mechanisms may differ between these epidemiologically and pathophysiologically associated conditions.
1	NA	NOC2L	NA	DISCUSS	We also describe potential functional underpinnings of risk loci, in particular for the locus on chromosome 1p36.33 in NOC2L, that require further detailed investigation
0	pancreatic cancer	NA	NA	METHODS	Participants were drawn from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4) and individuals were included from 16 cohort and 13 case-control studies genotyped in four previous GWAS phases, namely PanScan I, PanScan II, PanScan III, and PanC4.
0	NA	NA	NA	METHODS	Samples from the PANDoRA case-control consortium were used for replication.
0	NA	NA	NA	METHODS	The details on cases (individuals with PDAC) and controls have been previously described
0	NA	NA	NA	METHODS	All studies obtained informed consent from study participants and Institutional Review Board (IRB) approvals including IRB certifications permitting data sharing in accordance with the NIH Policy for Sharing of Data Obtained in NIH Supported or Conducted GWAS.
0	NA	NA	NA	METHODS	The PanScan and PanC4 GWAS data are available through dbGAP (accession numbers phs000206.v5.p3 and phs000648.v1.p1, respectively)
0	cancers	NA	NA	METHODS	Genotyping for PanScan was performed at the Cancer Genomics Research Laboratory (CGR) of the National Cancer Institute (NCI) of the National Institutes of Health (NIH) using the Illumina HumanHap series arrays (Illumina HumanHap550 Infinium II, Human 610-Quad) for PanScan I and II, respectively, and the Illumina Omni series arrays (OmniExpress, Omni1M, Omni2.5, and Omni5M) for PanScan III.
0	NA	NA	NA	METHODS	Genotyping for the PanC4 GWAS was performed at the Johns Hopkins Center for Inherited Disease Research (CIDR) using the Illumina HumanOmniExpressExome-8v1 array.
0	NA	NA	NA	METHODS	Imputation was performed using the 1000 Genomes (1000 G) Phase 3, Release 1 reference data set and IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) as previously described.
0	NA	NA	NA	METHODS	Because of the large overlap of variants on genotyping arrays for PanScan I and II, these data sets were imputed and analyzed together.
0	NA	NA	NA	METHODS	The PanScan III and PanC4 GWAS data sets were each imputed and analyzed separately.
0	NA	NA	NA	METHODS	For quality control, variants were excluded based on (1) completion rate <90%; (2) MAF <0.01; and (3) low-quality imputation score (IMPUTE2 INFO score <0.3).
0	pancreatic cancer	NA	NA	METHODS	After quality control, 11,381,182 SNPs genotyped or imputed in 5107 pancreatic cancer patients and 8845 controls of European ancestry were included in the analysis for PanScan I-III and 3933 cases and 3651 controls for PanC4 (Supplementary Table 1).
0	NA	NA	NA	METHODS	The association analysis was performed using SNPTEST (http://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) based on probabilistic genotype values from IMPUTE2, with parallel covariate adjustments: study, geographical region, age, sex, and principal components (PCA) of population substructure as were used in PanScan and study, age, sex, and PCA population substructure as were used in PanC4.
0	NA	NA	NA	METHODS	The score statistic of the log additive genetic association magnitude was used.
0	NA	NA	NA	METHODS	Summary statistics from PanScan I and II, PanScan III, and PanC4 were used for a meta-analysis using the fixed-effects inverse-variance method based on beta estimates and SEs (http://csg.sph.umich.edu/abecasis/metal/).
0	NA	NA	NA	METHODS	Heterogeneity was not observed for the SNPs identified as GWAS significant or suggestive in the combined study (Pheterogeneity >= 0.32).
1	NA	NA	rs13303010	METHODS	IMPUTE2 information scores were above 90% for SNPs (P < 1 x 10-6), except for rs13303010 in the PanScan I+II data (INFO = 0.42; Table 1).
0	NA	NA	NA	METHODS	The estimated inflation of the test statistic, lambda, was 1.002 for PanScan I+II, 1.051 for PanScan III, and 1.024 for PanC4
0	pancreatic cancer	NA	NA	METHODS	A Polygenic Risk Score (PRS) was constructed for each individual by summing the number of risk alleles carried for all established pancreatic cancer risk loci identified by GWAS, weighted by their estimated effect size.
0	pancreatic cancer	NA	NA	METHODS	Individuals were grouped by percentiles, and the association of the PRS (as percentile groupings) with pancreatic cancer was estimated using logistic regression
0	pancreatic cancer	NA	NA	METHODS	DEPICT analysis was used to prioritize causal genes at currently known pancreatic cancer risk loci identify gene sets enriched across risk loci, and tissues in which genes at risk loci are highly expressed.
0	NA	NA	NA	METHODS	No genes or SNP-gene pairs were significant at false discovery rate (FDR) < 0.05 (data not shown) but significant tissue enrichment is shown in Supplementary Table 7.
0	NA	NA	NA	METHODS	Additional gene set enrichment analysis was performed using GeneCodis3 (http://genecodis.cnb.csic.es/).
0	pancreatic cancer	NA	NA	METHODS	Genes (n = 65) were located in the currently known pancreatic cancer risk loci identified in subjects of European descent (for genes located +/-100 kb from the most significant SNP at the 22 risk loci) based on KEGG, Gene Ontology (Biological Process and Molecular Function) annotations using GeneCodis3 with reporting of FDR-corrected hypergeometric P values (Supplementary Table 8)
0	NA	NA	NA	METHODS	Ten promising signals (P < 10-6) were selected for replication in samples from the PANDoRA consortium.
0	cancers	NA	NA	METHODS	Genotyping was performed by custom TaqMan genotyping assays (Applied Biosystems) at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, for 2770 pancreatic cancer patients and 5178 controls, of which 2737 cases and 4753 controls had complete age and clinical data and did not overlap with other study individuals.
0	NA	NA	NA	METHODS	Duplicate quality-control samples (n = 607 pairs) showed 99.48% genotype concordance.
0	NA	NA	NA	METHODS	SNP quality metrics were performed for each SNP by plate; plates with <80% genotype completion rates were dropped from the analysis.
0	NA	NA	NA	METHODS	Individuals were excluded if they were missing data on two or more SNPs after excluding SNPs on plates with low genotype completion rates.
0	NA	NA	NA	METHODS	The association analysis for PANDoRA was adjusted for age and study in the same manner as previously described.
0	NA	NA	NA	METHODS	Heterogeneity between studies was assessed using the Cochran's Q-test.
0	NA	NA	NA	METHODS	Association analysis was also performed for the set of variants previously replicated in PANDoRA as part of the PanScan III and PanC4 GWAS studies (Supplementary Table 3)
0	NA	NA	NA	METHODS	Using SequenceLDhot, recombination hotspots for association plots were generated as previously described.
0	NA	NA	NA	METHODS	Recombination hotspot inference was performed using the 1000 G CEU samples (n = 99).
0	NA	NA	NA	METHODS	The LD heatmap was prepared using the 1000 G Phase 3 CEU data, and the snp.plotter R software package
0	NA	NA	NA	METHODS	The publicly available GTEx data (http://www.gtexportal.org/; version 6) were used to assess eQTLs in pancreatic tissue samples (n = 149).
0	NA	NA	NA	METHODS	RefSeq genes located within +/-500 kb of the marker SNP for each GWAS significant locus were assessed for cis-eQTL effects.
0	pancreatic cancer	NA	NA	METHODS	Nominally significant eQTLs from this analysis (P < 0.05) were then taken forward to further analysis in two additional pancreatic tissue sample sets: (1) the LTG and (2) The Cancer Genome Atlas (TCGA) pancreatic adenocarcinoma (PAAD) samples
0	cancers	NA	NA	METHODS	The LTG set included 95 histologically normal pancreatic tissue samples from participants of European ancestry collected at three participating sites: Mayo Clinic in Rochester, MN (45 samples, adjacent to tumor); Memorial Sloan Kettering Cancer Center in New York City, NY (34 samples, adjacent to tumor); and Penn State College of Medicine, Hershey, PA (16 samples, from tissue donors via the Gift of Life Donor Program, Philadelphia, PA) as previously described.
0	cancers	NA	NA	METHODS	Samples were confirmed to be non-tumorous with >=80% epithelial component by histological review and macro-dissected when needed.
0	NA	NA	NA	METHODS	The project was approved by the Institutional Review Board of each participating institution as well as the NIH
0	NA	NA	NA	METHODS	In short, RNA (RIN >7.5) isolated from fresh frozen histologically normal pancreatic tissue samples (LTG samples) with the Ambion mirVana kit was poly-A-enriched and subjected to massively parallel paired-end sequencing (Illumina's HiSeq2000/TruSeq v3 sequencing).
0	NA	NA	NA	METHODS	"MapSplice was used to align reads and RSEM (v1.2.14) for gene expression quantification (TPM) using the hg19/GRCh37-based UCSC ""RefSeq"" track for gene annotation."
0	NA	NA	NA	METHODS	DNA for genotyping was isolated from blood (Mayo Clinic samples), histologically normal fresh frozen pancreatic tissue samples (Penn State samples), or histologically normal fresh frozen spleen or duodenum tissue samples (MSKCC samples) using the Gentra Puregene Tissue Kit (Qiagen).
0	cancers	NA	NA	METHODS	DNA samples were genotyped on the Illumina OmniExpress or Omni1M arrays at the CGR of the Division of Cancer Epidemiology and Genetics, NCI, NIH.
0	NA	NA	NA	METHODS	After quality control, genotypes were imputed using the 1000 G (Phase 1, v3) imputation reference data set and IMPUTE 2.
0	NA	NA	NA	METHODS	Pre-imputation exclusion filters of Hardy Weinberg Equilibrium P < 1 x 10-6, minor allele frequency (MAF) <0.01, genotype missing rate >0.05, A/T and G/C pairs on ambiguous DNA strand (MAF > 0.45), and significantly different allele frequency between sample data and the 1000 G reference data (P < 7 x 10-8: Fisher's exact test) were used.
0	NA	NA	NA	METHODS	Post-imputation variants (single-nucleotide variants (SNP) and small insertion-deletion (indel) polymorphisms) with MAF < 0.05 or imputation quality scores (INFO score) <0.5 were removed from the final analysis
0	NA	NA	NA	METHODS	The second sample set included RNA-sequencing (RNA-seq) and genotype data from tumor-derived pancreatic samples obtained from TCGA PAAD data set by permission through the TCGA Data Access Committee.
0	cancers	NA	NA	METHODS	We excluded samples of non-European ancestry, with history of neo-adjuvant therapy prior to surgery, or with histological subtypes other than PDAC, leaving a total of 115 tumor samples for analysis.
0	pancreatic cancer	NA	NA	METHODS	TCGA mRNA-seq data (level 1 read data, generated using Illumina's HiSeq2000) for pancreatic cancer samples (TCGA PAAD) were processed in the same manner as the histologically normal LTG samples described above.
0	NA	NA	NA	METHODS	Blood-derived DNA samples for TCGA PAAD samples were genotyped on Affymetrix 6.0 arrays and processed in the same manner as for the LTG samples
0	NA	NA	NA	METHODS	The eQTL analysis was performed separately in histologically normal (LTG) and tumor-derived (TCGA PAAD) pancreatic samples using the Matrix eQTL (http://www.bios.unc.edu/research/genomic_software/Matrix_eQTL/) software package.
0	NA	NA	NA	METHODS	We tested associations between genotyped and imputed SNPs and the expression of genes evaluated by mRNA-sequencing after upper quantile normalization within samples and normal quantile transformation for each gene across samples by regressing the imputed dosage of the minor allele for each variant against normalized gene expression values.
0	NA	NA	NA	METHODS	Linear models were adjusted for age, sex, study, and the top five principal components (PCs) each for genotypes and gene expression to account for possible measured or hidden confounders.
0	NA	NA	NA	METHODS	The T-statistics from the linear regression is reported.
0	cancers	NA	NA	METHODS	For the tumor samples, we further adjusted for tumor stage and sequence-based tumor purity as per information provided by TCGA
0	allergy	NA	NA	METHODS	Variants at the new risk loci were assessed for potential functionality by examining their location in open (DNase Hypersensitivity Regions, DHS) and active chromatin (as per promoter and enhancer histone modification marks) in the ENCODE data.
0	NA	NA	NA	METHODS	For this, we used HaploReg 4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) and the UCSC Genome Browser (http://genome.ucsc.edu/).
1	NA	NA	NA	METHODS	Variants correlated with the most significant variant at each locus at r2 > 0.7 in 1000 G EUR populations were included, except for 1p36.33/NOC2L where P value LR > 1:100 was used
0	NA	NA	NA	METHODS	Candidate functional variants at 1p36.33 were selected by comparing the likelihood of each variant from the association analysis with the likelihood of the most significant variant.
1	NA	rank 5	rs13303010	METHODS	Ten variants had likelihood ratios, LR > 1:100 relative to the most significant SNP: rs13303010 (P value rank 1), rs13303327 (rank 2), rs113491766 (rank 3), rs3935066 (rank 4), rs111748052 (rank 5), rs10465242 (rank 6), rs13303160 (rank 7), rs7524174 (rank 8), rs13302957 (rank 9), and rs4970445 (rank 10).
1	NA	NA	rs13303010	METHODS	They were all highly correlated with rs13303010 (r2 = 0.52-1.00, 1000 G EUR data).
0	NA	NA	NA	METHODS	These 10 variants were considered the set of variants most likely to contain the functional variant(s) at 1p36.33.
0	NA	NA	NA	METHODS	Possible allelic effects of these top 10 variants on TF-binding motifs were determined using PrEdict Regulatory Functional Effect of SNPs by Approximate P value Estimation (PERFECTOS-APE; http://opera.autosome.ru/perfectosape/) analysis that determines the probability of a TF motif (using position weight matrices, from HOCOMOCO-10, JASPAR, HT-SELEX, SwissRegulon, and HOMER databases) in the DNA sequence overlapping each variant.
0	NA	NA	NA	METHODS	The fold change in probability of there being a TFBS present for each allele of a variant is then calculated.
0	NA	NA	rs111748052	METHODS	Two dbSNP variants at 1p36.33 with the same bp location, rs111748052 (-/ATTTT) and rs10465241 (C/T), may be two independent variants (as indicated in dbSNP), or a single tri-allelic marker (alleles are shown as C/CATTTT/T in 1000 G).
0	NA	NA	rs111748052	METHODS	As PERFECTOS-APE does not analyze indel variants, we analyzed the two indels among the 10 potential functional variants, rs111748052 and rs113491766, using a different program, sequence TF Affinity Prediction.
0	NA	NA	NA	METHODS	This program calculates the total affinity of a sequence for a TF (as given by TRANSFAC and JASPAR databases) on the basis of a biophysical model of the binding energies between a TF and DNA.
0	NA	NA	NA	METHODS	The probability for a given TFBS for each variant of the indel was then compared as in PERFECTOS-APE to determine the fold change effect of the indel on the presence of the TFBS
1	NA	NOC2L	NA	METHODS	Gene expression was assessed for genes that are closest to the reported variants at chromosomes 1p36.33: NOC2L, KLHL17, and PLEKHN1; 7p12: TNS3; 8q21.11: HNF4G; 17q12: HNF1B; 18q21.32: GRP, as well as two additional genes at 1p36.33 exhibiting nominally significant eQTLs in GTEx (1p36.33/SAMD11/DVL1).
0	pancreatic cancer	NA	NA	METHODS	We assessed differential expression of these genes in pancreatic tumor samples (PDAC, n = 8), histologically normal (non-malignant) pancreatic tissue samples (n = 10), and pancreatic cell lines (n = 9) by RNA-seq as described previously.
0	cancers	NA	NA	METHODS	We compared gene expression in tumors (T) and cell lines (C) to histologically normal pancreatic tissue samples (N) by EdgeR analysis.
0	cancers	NA	NA	METHODS	P values for differential expression in tumor vs. normal (TvN) and Cell lines vs. normal (CvN) represent an exact statistic using the normalized pseudo-counts and tagwise dispersion estimates per gene
0	NA	NA	NA	METHODS	The PanScan and PanC4 genome-wide association data that support the findings of this study are available through dbGAP (accession numbers phs000206.v5.p3 and phs000648.v1.p1, respectively)
0	NA	NA	NA	AUTH_CONT	A.P.K., R.S.S., L.T.A., B.M.W., G.M.P., and H.A.R.
0	NA	NA	NA	AUTH_CONT	organized and designed the study.
0	NA	NA	NA	AUTH_CONT	A.P.K., L.T.A., F.C., J.W.H., A.J., J.Z., and M.B.
0	NA	NA	NA	AUTH_CONT	organized and supervised the genotyping of samples.
0	NA	NA	NA	AUTH_CONT	E.J.C., E.M., O.O., M.Z., A.Blackford.
0	NA	NA	NA	AUTH_CONT	L.T.A., F.C., P.K., J.W.H., A.J., J.Z., F.Chen, and A.P.K.
0	NA	NA	NA	AUTH_CONT	designed and conducted the statistical analysis.
0	NA	NA	NA	AUTH_CONT	A.P.K.
0	NA	NA	NA	AUTH_CONT	and L.T.A.
0	NA	NA	NA	AUTH_CONT	drafted the first version of the manuscript.
0	NA	NA	NA	AUTH_CONT	A.P.K., B.M.W., H.A.R., R.Z.S.-S., F.C., D.A., G.A., A.A.A., A.B., W.R.B., L.B.-F., S.I.B., A.Borgida, P.M.B., L.B., P.B., H.B., B.B.-d.-M., J.B., D.C., G.C., G.C., G.M.C., K.G.C., C.C.C., S.C., M.C., F.D., E.J.D., L.F., C.F., N.F., S.G., J.M.M.G., M.Gazouli, G.G.G., E.G., M.G., G.E.G., P.J.G., T.H., C.H., P.H., M.H., P.H., K.J.H., J.H., I.H., E.A.H., R.H., R.J.H., E.J.J., K.J., V.J., R.K., K.-T.K., E.A.K., M.K., C.K., M.H.K., J.K., R.J.K., D.L., S.L., R.T.L., I.-M.L., L.L., L.Lu., N.M., A.M., S.M., R.L.M., B.M.-D., R.E.N,.
0	NA	NA	NA	AUTH_CONT	J.P.N., A.L.O., I.O., C.P., A.V.P., U.P., R.P., M.P., F.X.R., N.R., G.S., H.D.S., G.S., X.-O.S., D.S., J.P.S., P.S., M.S., R.T.-W., F.T., M.D.T., G.S.T., S.K.V., Y.V., K.V., P.V., J.W.-W., Z.W., N.W., E.W., H.Y., K.Y., A.Z.-J., W.Z., P.K., D.L., S.C., O.O., G.M.P., and L.T.A.
0	NA	NA	NA	AUTH_CONT	conducted the epidemiological studies and contributed samples to the GWAS, expression and/or follow-up genotyping.
0	NA	NA	NA	AUTH_CONT	All authors contributed to the writing of the manuscript
